Skip to main content
Erica Warlick, MD, Oncology, Minneapolis, MN, M Health Fairview University of Minnesota Medical Center

EricaDahlWarlickMD

Oncology Minneapolis, MN

Hematologic Oncology

Assistant Professor, Medicine, University of Minnesota Medical School

Dr. Warlick is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Warlick's full profile

Already have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 2001 - 2004
  • University of Minnesota Medical School
    University of Minnesota Medical SchoolClass of 2001

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2007 - 2025
  • MD State Medical License
    MD State Medical License 2004 - 2007
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment Kinetics  
    Erhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica

Abstracts/Posters

  • Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disea...
    Erica D. Warlick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Predicted Leukocyte Telomere Length and Risk of Myeloid Neoplasms
    Erica D. Warlick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multip...
    Erica D. Warlick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • GT Biopharma Announces Solid Tumor Targeting TriKe™ Kills Non-Small Cell Lung Cancer (NSCLC) Tumor Cells
    GT Biopharma Announces Solid Tumor Targeting TriKe™ Kills Non-Small Cell Lung Cancer (NSCLC) Tumor CellsOctober 22nd, 2019
  • GT Biopharma Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected Cells
    GT Biopharma Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected CellsOctober 3rd, 2019
  • GT Biopharma Announces HIV Trike™ Data to Be Published
    GT Biopharma Announces HIV Trike™ Data to Be PublishedSeptember 26th, 2019
  • Join now to see all

Hospital Affiliations